<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354064</url>
  </required_header>
  <id_info>
    <org_study_id>201903142</org_study_id>
    <nct_id>NCT04354064</nct_id>
  </id_info>
  <brief_title>Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors</brief_title>
  <official_title>Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Sequencing Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barnes Jewish Health Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier detection of disease recurrence will enable greater treatment options and has strong
      potential to improve patient outcomes. This project is translational and has the potential to
      lead to future translational research opportunities, including interventional trials in which
      therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular
      residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the
      clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and
      prognosis, and guide clinical decision-making in this era of personalized precision medicine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from progression</measure>
    <time_frame>Through completion of study (estimated to be 6.5 years)</time_frame>
    <description>-Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Through completion of study (estimated to be 6.5 years)</time_frame>
    <description>-Defined as post-treatment ctDNA detection or RECIST 1.1 based radiographic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>Through completion of study (estimated to be 6.5 years)</time_frame>
    <description>-Defined as death from cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through completion of study (estimated to be 6.5 years)</time_frame>
    <description>-Defined as death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>Through completion of study (estimated to be 6.5 years)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3362</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Genitourinary Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Solid Tumor Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Skin Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Healthy Donor Samples</arm_group_label>
    <description>Donation of blood and/or urine samples as often as monthly and as many as 12 times in total
These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Samples from Repository and Banking Studies</arm_group_label>
    <description>Healthy prostate and/or blood and/or urine samples from Genitourinary Repository
Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies
Tissue and/or blood samples from Esophageal Repository
Tissue and/or blood samples from Genitourinary Repository
Tissue and/or plasma from Sarcoma Tissue Bank
Tissue and/or plasma from Breast Cancer Bank
Tissue, plasma, and/or urine from GI Tissue and Blood Bank
Tissue, blood, and/or urine from Solid Tumor Bank
Tissue, blood, and/or urine from Lung Cancer Bank
Tissue and/or blood from Skin Cancer Bank</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood and/or urine from healthy volunteers under this study

        -  The remaining samples (tissue, blood, drain fluid, urine, plasma) will be collected
           under various repository and banking studies at Washington University School of Medicine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  This study will access data and specimens from patients who consented to solid tumor
             banks (approximately 3262 patients) There is a waiver of consent for this study
             regarding patient data banked under the tissue banks.

          -  Healthy donors will be consented prior to sample acquisition (approximately 100
             patients)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AJCC 8th Edition stage I-IV pathologically-confirmed cancer of solid
             tumor origin

          -  Eligible healthy donors will be at least 18 years of age.

        Exclusion Criteria:

          -  Healthy donors younger than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aadel Chaudhuri, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aadel Chaudhuri, M.D., Ph.D.</last_name>
    <phone>314-273-2931</phone>
    <email>aadel@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aadel Chaudhuri, M.D., Ph.D.</last_name>
      <phone>314-273-2931</phone>
      <email>aadel@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Aadel Chaudhuri, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Harris, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Re-I Chin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiram Gay, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mackenzie Daly, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wade Thorstad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Zevallos, M.D., MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sidharth Puram, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Varun Puri, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Maher, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ha Dang, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russell Pachynski, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Jones, B.A.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Hsieh, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zachary Smith, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruna Pellini Ferreira, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Arora, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Van Tine, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Hirbe, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Spraker, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Ma, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imran Zoberi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foluso Ademuyiwa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Fields, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koushik Das, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Ramirez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Chen, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification will be available for sharing with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

